ReviewWorld journal of gastroenterology2014
Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance.
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02959255 (A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin), which is not on this map. Cited by 51 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Strategy for the Eradication of H. Pylori Infection
Who cites it
51 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Bibliometric and visualisation analyses of gastric ulcer knowledge areas and emerging trends, 2004-2024.Frontiers in medicine · 2025Pooled it
- Clinical relevance of the cagA and vacA s1m1 status and antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis.BMC infectious diseases · 2022Pooled it
- Hybrid, sequential and concomitant therapies for Helicobacter pylori eradication: A systematic review and meta-analysis.World journal of gastroenterology · 2016Pooled it
- Tailored Therapy Versus Empiric Chosen Treatment for Helicobacter pylori Eradication: A Meta-Analysis.Medicine · 2016Pooled it
- Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for Helicobacter pylori eradication in Italy.World journal of gastroenterology · 2015Trial
- Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade "A" Success Rate for First-Line Helicobacter pylori Eradication.BioMed research international · 2015Trial
- A Comprehensive Review of Plant and Microbial Natural Compounds as Sources of PotentialBiotech (Basel (Switzerland)) · 2025Review
- Copper enhances tetracycline resistance via the efflux transporter CrdAB-CzcBA inFrontiers in medicine · 2025Article
- The oncobiome; what, so what, now what?Microbiome research reports · 2025Review
- Review
- Equivalence Trial of the Non-Bismuth 10-Day Concomitant and 14-Day Hybrid Therapies forAntibiotics (Basel, Switzerland) · 2024Article
- Local and Systemic Effects of Bioactive Food Ingredients: Is There a Role for Functional Foods to Prime the Gut for Resilience?Foods (Basel, Switzerland) · 2024Review
- Recombinant L. lactis vaccine LL-plSAM-WAE targeting four virulence factors provides mucosal immunity against H. pylori infection.Microbial cell factories · 2024Article
- Sustain-release lipid-liquid crystal formulations of pexiganan against Helicobacter pylori infection: in vitro evaluation in C57BL/6 mice.BMC pharmacology & toxicology · 2024Article
- Clarithromycin-induced acute liver injury in a patient with positiveAnnals of medicine and surgery (2012) · 2023Article
- Susceptibility patterns and virulence genotypes ofWorld journal of gastroenterology · 2023Article
- Current Worldwide Trends in PediatricChildren (Basel, Switzerland) · 2023Review
- Helicobacter Pylori: A Review of Current Treatment Options in Clinical Practice.Life (Basel, Switzerland) · 2022Review
- Clinical Implications ofAntibiotics (Basel, Switzerland) · 2022Review
- The Challenges of Eradicating PediatricChildren (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of Helicobacter pylori (H. pylori) infection is paramount for the management of prevalent gastrointestinal disorders including peptic ulcer disease and gastric cancer. Due to the wide increase in prevalence of H. pylori resistance to antibiotics, clarithromycin-based triple therapies are not any more suitable for unconditional empiric use, and should not be recommended, unless local resistance to this antibiotic is low (< 20%). Alternative strategies have been proposed to overcome the issue of increasing clarithromycin resistance, and some of them are already implemented in clinical practice. These comprise: (1) adoption of novel, more effective, empirical treatments: bismuth quadruple, sequential, non-bismuth quadruple (concomitant), dual-concomitant (hybrid), and levofloxacin-based regimens, the latter mainly designated as second-line/rescue options; (2) perspectives for a susceptibility-guided (tailored) therapeutic approach based on culture-free molecular testing methods; and (3) adjunct use of probiotics to improve eradication rates. The present article is aimed to provide a comprehensive overview of current and emerging strategies in the treatment of H. pylori infection, focusing on the challenge of antimicrobial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.